Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Standard
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. / Schmidinger, Manuela; Arnold, Dirk; Szczylik, Cezary; Wagstaff, John; Ravaud, Alain.
In: CANCER INVEST, Vol. 28, No. 8, 8, 2010, p. 856-864.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
AU - Schmidinger, Manuela
AU - Arnold, Dirk
AU - Szczylik, Cezary
AU - Wagstaff, John
AU - Ravaud, Alain
PY - 2010
Y1 - 2010
N2 - Sunitinib is a reference standard of care for the treatment of metastatic renal cell carcinoma (mRCC). While the tolerability of sunitinib is consistent across clinical studies, the impact of tolerability on clinical benefit necessitates effective therapy management, focusing on optimization of dosing, treatment duration, and management of adverse events. Managing individual tolerability concerns in clinical practice should include patient education and practical management strategies. We review the sunitinib tolerability profile in mRCC and describe practical strategies to manage adverse events in order to maximize clinical benefit. These strategies may allow long-term sunitinib treatment, thereby optimizing the available clinical efficacy.
AB - Sunitinib is a reference standard of care for the treatment of metastatic renal cell carcinoma (mRCC). While the tolerability of sunitinib is consistent across clinical studies, the impact of tolerability on clinical benefit necessitates effective therapy management, focusing on optimization of dosing, treatment duration, and management of adverse events. Managing individual tolerability concerns in clinical practice should include patient education and practical management strategies. We review the sunitinib tolerability profile in mRCC and describe practical strategies to manage adverse events in order to maximize clinical benefit. These strategies may allow long-term sunitinib treatment, thereby optimizing the available clinical efficacy.
KW - Humans
KW - Proportional Hazards Models
KW - Clinical Trials as Topic
KW - Antineoplastic Agents adverse effects
KW - Neoplasm Metastasis drug therapy
KW - Dose-Response Relationship, Drug
KW - Fatigue chemically induced
KW - Indoles adverse effects
KW - Drug Tolerance
KW - Angiogenesis Inhibitors adverse effects
KW - Asthenia chemically induced
KW - Carcinoma, Renal Cell drug therapy
KW - Kidney Neoplasms drug therapy
KW - Medical History Taking
KW - Pyrroles adverse effects
KW - Humans
KW - Proportional Hazards Models
KW - Clinical Trials as Topic
KW - Antineoplastic Agents adverse effects
KW - Neoplasm Metastasis drug therapy
KW - Dose-Response Relationship, Drug
KW - Fatigue chemically induced
KW - Indoles adverse effects
KW - Drug Tolerance
KW - Angiogenesis Inhibitors adverse effects
KW - Asthenia chemically induced
KW - Carcinoma, Renal Cell drug therapy
KW - Kidney Neoplasms drug therapy
KW - Medical History Taking
KW - Pyrroles adverse effects
M3 - SCORING: Zeitschriftenaufsatz
VL - 28
SP - 856
EP - 864
JO - CANCER INVEST
JF - CANCER INVEST
SN - 0735-7907
IS - 8
M1 - 8
ER -
